5 Of The Best Stocks Under $10 For 2017

Here at Zacks, we don’t generally classify stocks as “cheap” or “expensive,” and rather than looking at the stock’s face value, we have a system that puts an emphasis on earnings estimate revisions to find stocks that will hopefully be winners for investors.

That being said, low-priced stocks can be attractive to smaller investors that can’t necessarily afford large stakes in companies with higher priced stocks. When looking at these low-priced stocks, we can look at the same trends in growth, value, and momentum and apply the Zacks Rank to properly analyze the potential that these companies have.

Today we’ve highlighted five stocks that are currently trading for under $10 per share. These stocks are also showing signs for solid growth in 2017, and all of them currently hold a Zacks Rank #1 (Strong Buy).

1.       Codexis, Inc. (CDXS - Free Report)

Prior Close: $4.60

Codexis is a protein engineering company that applies its technology to the development of biocatalysts for the commercial manufacture of pharmaceuticals and fine chemicals. While analysts expect Codexis to remain a loss-making company in 2017, we have seen one positive earnings estimate revision for the year and current estimates would represent sales growth of 12.88% and EPS growth of 64.29%.

2.       EMCORE Corporation (EMKR - Free Report)

Prior Close: $8.70

Emcore is a provider of compound semiconductor-based products for the broadband, fiber optic, satellite, and terrestrial solar power markets. After ending 2016 with a month that saw the stock gain over 30%, the company is looking to continue its momentum in 2017. Right now, our consensus estimates for the year would represent sales growth of 8.11% and EPS growth of 14.71%.

3.       Intevac, Inc. (IVAC - Free Report)

Prior Close: $8.55

Intevac is a supplier of static sputtering systems and related manufacturing equipment used to manufacture thin-film disks for computer hard disk drives. This stock gained nearly 82% in 2016, and its projected growth metrics suggest that it continue climbing this year. Our current consensus estimates would represent sales growth of 27.00% and earnings growth of 103.91%. In fact, Intevac is projected to post an annual profit in 2017.

4.       Organovo Holdings (ONVO - Free Report)

Prior Close: $3.39

Organovo Holdings is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications. This is an incredibly innovative field, and Organovo looks poised to become a leader in the industry soon. For its fiscal year that ends in March, the company is expected to post sales growth of 264.96%. Sales growth for the fiscal year that ends in March 2018 is expected be nearly 100%.

5.       StarTek, Inc. (SRT - Free Report)

Prior Close: $8.45

StarTek is a global provider of process management services and owns and operates branded vertical market Internet web sites. StarTek was another one of 2016’s biggest success stories, as the stock gained nearly 120% on the year. The company is poised for another solid year with consensus estimates that project sales growth of 6.21% and earnings growth of 660%.

Bottom Line

A stock’s market price is certainly not the most important factor to consider when considering whether or not to add it to your portfolio, and sales and earnings growth projections can prove to be tough to live up to. 

more

How did you like this article? Let us know so we can better customize your reading experience.

Comments